Advancing Cancer Immunotherapy through Innovative Approaches
Update: 2025-12-23
Description
Valora Therapeutics is exploring a new approach to increase response rates for cancer immunotherapy by developing AbLecs and moving towards clinical trials. This startup, alongside companies like Calidi Biotherapeutics Inc., aims to address the limited success of immunotherapy in treating cancer patients. For more insights on biotechnology and biomedical sciences, visit BioMedWire.com.
Comments
In Channel



